Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PolyPid ( (PYPD) ) just unveiled an announcement.
On June 25, 2025, PolyPid Ltd. held its Annual and Extraordinary General Meeting of Shareholders, where all proposed resolutions were approved. These included the re-election of the company’s independent accountants and board members, approval of compensation for directors, and option grants for the CEO and non-executive directors. The meeting also saw the approval of the company’s updated compensation policy, which aims to align the interests of officers with those of the company and its stakeholders, ensuring long-term economic value.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. operates in the pharmaceutical industry, focusing on the development of innovative antibiotic solutions to address unmet medical needs. The company is known for its proprietary PLEX technology, which is designed to provide controlled and prolonged release of medications, primarily targeting surgical site infections.
Average Trading Volume: 464,668
Technical Sentiment Signal: Sell
Current Market Cap: $37.5M
For an in-depth examination of PYPD stock, go to TipRanks’ Overview page.